Search

everythinglearnresearchcommunity

for

Search:↓

The user experiences irritation from alcohols in minoxidil and is considering alternatives like trichosol mixed with polyethylene glycol or DMSO. They seek advice on the best nonirritating option.

Pyrilutamide is being discussed as a potential hair loss treatment, but opinions are mixed, with some users skeptical about its effectiveness and the company's credibility. Some users report combining pyrilutamide with other treatments like dutasteride and microneedling, noting improvements, while others remain doubtful.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.

People have reported hair thickening with Pyrilutamide, particularly using a 1% concentration. Some users are curious about the availability of different concentrations like 0.9%.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

The user has been using pyrilutamide, topical finasteride, and 15% minoxidil for hair growth for almost 4 years. Despite mixed responses from others, the user reports seeing progress, especially with the addition of pyrilutamide, and plans to continue the regimen.

Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.

Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.

DUPA is considered more treatable than FAPD, as FAPD involves scarring that prevents hair regrowth. The user has started treatment with oral dutasteride and minoxidil, hoping for better results than previous treatments.

A 34-year-old woman is experiencing diffuse hair loss and irregular periods, possibly due to long-term spironolactone use. She is considering minoxidil and finasteride for treatment and seeking medical advice for androgenic alopecia and hormonal imbalances.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

The user experienced side effects from a hair loss treatment and is considering using pyrilutamide, alfatradiol, and possibly minoxidil. They are unsure about starting minoxidil immediately or waiting to see the effects of the other treatments.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The conversation discusses struggles with diffuse thinning and hair loss treatments, including the use of dutasteride, minoxidil, and finasteride, with limited success. The original poster regrets having a hair transplant at 21 due to weak donor hair and ongoing thinning.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.